Clinical Trials Browser

Phase 2 × Ovarian Neoplasms × MLN 8237 × Clear all

NCT00853307 2022-04-08

MLN8237 for Treatment of Participants With Ovarian, Fallopian Tube, or Peritoneal Carcinoma

Phase 2 Completed

31 enrolled 19 charts

Ovarian Neoplasms

NCT01091428 2018-06-04

Alisertib (MLN8237) in Participants With Ovarian, Fallopian Tube or Peritoneal Cancer Preceded by Phase 1 Study of MLN8237 Plus Paclitaxel Treatment of Ovary or Breast Cancer

Phase 2 Completed

191 enrolled 39 charts

BreastGynecologic

Breast Neoplasms, Fallopian Tube Neoplasms, Ovarian Neoplasms